• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc

    8/14/25 8:30:21 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Royalty Pharma plc

    (Name of Issuer)


    Class A ordinary shares, par value US$0.0001 per share

    (Title of Class of Securities)


    G7709Q104

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic (RP) Collections, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GA RP Holding, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic Partners AIV-1 A, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic Partners AIV-1 B, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GAP Coinvestments CDA, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GAP Coinvestments III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GAP Coinvestments IV, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GAP Coinvestments V, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic (SPV) GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic GenPar, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,243,870.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,243,870.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,243,870.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic Partners (Bermuda) EU, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic Partners (Bermuda) IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic Partners (Lux) SCSp
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic GenPar (Lux) SCSp
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic (Lux) S.a r.l.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    General Atlantic GenPar (Bermuda), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GAP (Bermuda) L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    G7709Q104


    1Names of Reporting Persons

    GA RP Holding, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Royalty Pharma plc
    (b)Address of issuer's principal executive offices:

    110 East 59th Street, New York, NY 10022
    Item 2. 
    (a)Name of person filing:

    This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) General Atlantic, L.P. ("GA LP"); (ii) General Atlantic (RP) Collections, LLC ("GA RP Collections"); (iii) GA RP Holding, L.P. ("GA RP Holding"); (iv) General Atlantic Partners AIV-1 A, L.P. ("GAP AIV-1 A"); (v) General Atlantic Partners AIV-1 B, L.P. ("GAP AIV-1 B"); (vi) GAP Coinvestments CDA, L.P. ("GAPCO CDA"); (vii) GAP Coinvestments III, LLC ("GAPCO III"); (viii) GAP Coinvestments IV, LLC ("GAPCO IV"); (ix) GAP Coinvestments V, LLC ("GAPCO V"); (x) General Atlantic (SPV) GP, LLC ("GA SPV"); (xi) General Atlantic GenPar, L.P. ("GenPar"); (xii) General Atlantic Partners (Bermuda) EU, L.P. ("GAP EU"); (xiii) General Atlantic Partners (Bermuda) IV, L.P. ("GAP IV"); (xiv) General Atlantic Partners (Lux) SCSp ("GAP Lux"); (xv) General Atlantic GenPar (Lux) SCSp ("GAP GenPar Lux"); (xvi) General Atlantic (Lux) S.a.r.l. ("GA Lux"); (xvii) General Atlantic GenPar (Bermuda), L.P. ("GenPar Bermuda"); (xviii) GAP (Bermuda) L.P. ("GAP (Bermuda) L.P."); and (xix) GA RP Holding, Ltd. ("GA RP Holding, Ltd.").
    (b)Address or principal business office or, if none, residence:

    The principal address of each of the Reporting Persons (other than GAP Lux, GAP GenPar Lux and GA Lux) is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The principal address of each of GAP Lux, GAP GenPar Lux and GA Lux is 412F, route d'Esch, L-1471 Luxembourg, Grand Duchy of Luxembourg.
    (c)Citizenship:

    See Row (4) of each Reporting Person's cover page.
    (d)Title of class of securities:

    Class A ordinary shares, par value US$0.0001 per share
    (e)CUSIP No.:

    G7709Q104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 30, 2025, the Reporting Persons owned the following number of the Company's Class A ordinary shares: (i) GA LP owned of record 0 Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (ii) GA RP Collections has an indirect ownership interest in 14,243,870 Class B ordinary shares of the Company corresponding to an equal number of Class B interests of Royalty Pharma Holdings Ltd, a subsidiary of the Company, each convertible at the option of the holder into one Class A ordinary shares, or approximately 3.2% of the issued and outstanding Class A ordinary shares (iii) GA RP Holding owned of record 0 Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (iv) GAP AIV-1 A owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (v) GAP AIV-1 B owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (vi) GAPCO CDA owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (vii) GAPCO III owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (viii) GAPCO IV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (ix) GAPCO V owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (x) GA SPV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xi) GenPar owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xii) GAP EU owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xiii) GAP IV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xiv) GAP Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xv) GAP GenPar Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xvi) GA Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xvii) GenPar Bermuda owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xviii) GAP (Bermuda) L.P. owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares (xix) GA RP Holding, Ltd. owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares The members of GA RP Collections that share beneficial ownership of the Class A ordinary shares held of record by GA RP Collections are indirectly held by the following General Atlantic investment funds, (the "GA Funds"): GAP AIV-1 A, GAP AIV-1 B, GAPCO CDA, GAPCO III, GAPCO IV and GAPCO V. GA SPV is the sole non-member manager of GA RP Collections. The general partner of GAP AIV-1 A and GAP AIV-1 B is GenPar. The general partner of GenPar is GA LP. GA LP is the sole member of GA SPV, the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. The limited partners that share beneficial ownership of the Class A ordinary shares held by GA RP Holding are the following General Atlantic investment funds: GAP EU, GAP IV, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA. The general partner of GAP Lux is GAP GenPar Lux and the general partner of GAP GenPar Lux is GA Lux. The general partner of GAP EU, GAP IV and GA Lux is GenPar Bermuda. GAP (Bermuda) L.P. is the general partner of GenPar Bermuda. The general partner of GA RP Holding is GA RP Holding, Ltd. ("GA RP Holding, Ltd."). GAP (Bermuda) L.P. is the sole shareholder of GA RP Holding, Ltd. GA LP and GAP (Bermuda) L.P. are controlled by the Partnership Committee of GASC MGP, LLC (the "GA Partnership Committee"). There are five members of the GA Partnership Committee. GA LP, GAP (Bermuda) L.P., GA RP Holdings Ltd., GenPar Bermuda, GA Lux, GAP GenPar Lux, GAP Lux, GAP IV, GAP EU, GenPar, GA SPV, GAP AIV-1 A, GAP AIV-1 B, GAPCO III, GAPCO IV, GAPCO V, GAPCO CDA are a "group" within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934, as amended. Each of the members of the GA Partnership Committee disclaims ownership of the Class A ordinary shares reported herein except to the extent he has a pecuniary interest therein. The name, the business address and the citizenship of each of the members of the GA Partnership Committee as of the date hereof is attached hereto as Schedule A and is hereby incorporated by reference. Amount Beneficially Owned: By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own the Class A ordinary shares indicated on row (9) on such Reporting Person's cover page included herein.
    (b)Percent of class:

    All calculation of percentage ownership herein are based on an aggregate of 446,536,920 Class A ordinary shares outstanding, consisting of (i) 432,293,050 Class A ordinary shares reported by the Company to be outstanding as of August 1, 2025, as reflected in the Company's Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission on August 6, 2025, and (ii) 14,243,870 Class A ordinary shares issuable upon conversion of Class B interests of Royalty Pharma Holdings held by GA RP Collections.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Each of the Reporting Persons may be deemed to have the sole power to direct the voting of the shares of common stock indicated on Row (5) of each such Reporting Person's cover page included herein.

     (ii) Shared power to vote or to direct the vote:

    Each of the Reporting Persons may be deemed to share the power to direct the voting of the shares of common stock indicated on Row (6) of each such Reporting Person's cover page included herein.

     (iii) Sole power to dispose or to direct the disposition of:

    Each of the Reporting Persons may be deemed to have the sole power to direct the dispositions of the shares of common stock indicated on Row (7) of each such Reporting Person's cover page included herein.

     (iv) Shared power to dispose or to direct the disposition of:

    Each of the Reporting Persons may be deemed to share the power to direct the dispositions of the shares of common stock indicated on Row (8) of each such Reporting Person's cover page included herein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Item 2, which states the identity of the members of the group filing this Schedule 13G.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    General Atlantic, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director
    Date:08/14/2025
     
    General Atlantic (RP) Collections, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic L.P., the sole member of General Atlantic SPV (GP), LLC, its sole non-member manager
    Date:08/14/2025
     
    GA RP Holding, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the GP of GAP (Bermuda) L.P., the sole shareholder of GA RP Holding, Ltd., its GP
    Date:08/14/2025
     
    General Atlantic Partners AIV-1 A, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., the general partner of General Atlantic GenPar, L.P., its general partner
    Date:08/14/2025
     
    General Atlantic Partners AIV-1 B, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., the general partner of General Atlantic GenPar, L.P., its general partner
    Date:08/14/2025
     
    GAP Coinvestments CDA, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its general partner
    Date:08/14/2025
     
    GAP Coinvestments III, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
    Date:08/14/2025
     
    GAP Coinvestments IV, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
    Date:08/14/2025
     
    GAP Coinvestments V, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its managing member
    Date:08/14/2025
     
    General Atlantic (SPV) GP, LLC
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its sole member
    Date:08/14/2025
     
    General Atlantic GenPar, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of General Atlantic, L.P., its general partner
    Date:08/14/2025
     
    General Atlantic Partners (Bermuda) EU, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the GP of GAP (Bermuda) L.P., the GP of GenPar Bermuda, its GP
    Date:08/14/2025
     
    General Atlantic Partners (Bermuda) IV, L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the GP of GAP (Bermuda) L.P., the GP of GenPar Bermuda, its GP
    Date:08/14/2025
     
    General Atlantic Partners (Lux) SCSp
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A of General Atlantic (Lux) S.a r.l., the general partner of General Atlantic GenPar (Lux) SCSp, its general partner
    Date:08/14/2025
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B of General Atlantic (Lux) S.a r.l., the general partner of General Atlantic GenPar (Lux) SCSp, its general partner
    Date:08/14/2025
     
    General Atlantic GenPar (Lux) SCSp
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A of General Atlantic (Lux) S.a r.l., its general partner
    Date:08/14/2025
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B of General Atlantic (Lux) S.a r.l., its general partner
    Date:08/14/2025
     
    General Atlantic (Lux) S.a r.l.
     
    Signature:/s/ Ingrid van der Hoorn
    Name/Title:Ingrid van der Hoorn, Manager A
    Date:08/14/2025
     
    Signature:/s/ William Blackwell
    Name/Title:William Blackwell, Manager B
    Date:08/14/2025
     
    General Atlantic GenPar (Bermuda), L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the general partner of GAP (Bermuda) L.P., its general partner
    Date:08/14/2025
     
    GAP (Bermuda) L.P.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, its general partner
    Date:08/14/2025
     
    GA RP Holding, Ltd.
     
    Signature:/s/ Michael Gosk
    Name/Title:Michael Gosk, Managing Director of GAP (Bermuda) GP Limited, the general partner of GAP (Bermuda) L.P., its sole shareholder
    Date:08/14/2025
    Exhibit Information

    Exhibit 1 - Agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)(1) under the Act (previously filed). https://www.sec.gov/Archives/edgar/data/1017645/000095014221000545/eh210130208_13g-rp.htm

    Get the next $RPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. "We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "His experience as a seasoned chief executive of a public company together with his exceptional business acumen has been invaluable to Royalty Pharma duri

    8/13/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Reports Second Quarter 2025 Results

    Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) --  Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Additionally, we

    8/6/25 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Declares Third Quarter 2025 Dividend

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

    7/18/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc

    SCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)

    8/14/25 8:30:21 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    8/13/25 4:33:18 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Royalty Pharma plc

    SCHEDULE 13G - Royalty Pharma plc (0001802768) (Subject)

    8/13/25 12:49:42 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Norden Gregory sold $1,213,749 worth of Class A Ordinary Shares (33,500 units at $36.23) and converted options into 144,660 units of Class A Ordinary Shares, increasing direct ownership by 133% to 194,848 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/11/25 4:35:58 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, Chairman of the Board Legorreta Pablo G. was granted 21,901 units of Class A Ordinary Shares, increasing direct ownership by 2% to 904,396 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 5:00:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Coyne Terrance P. was granted 3,696 units of Class A Ordinary Shares (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 4:58:17 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma downgraded by UBS with a new price target

    UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

    6/3/24 9:17:33 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Royalty Pharma with a new price target

    UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

    6/14/22 7:27:46 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

    Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr

    7/17/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

    4/8/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

    NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

    7/24/24 8:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Financials

    Live finance-specific insights

    View All

    Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. "We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "His experience as a seasoned chief executive of a public company together with his exceptional business acumen has been invaluable to Royalty Pharma duri

    8/13/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Reports Second Quarter 2025 Results

    Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) --  Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Additionally, we

    8/6/25 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Declares Third Quarter 2025 Dividend

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

    7/18/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    11/8/24 3:15:49 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

    SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

    7/29/24 4:30:11 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    2/13/24 10:17:30 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care